Range of Treatment Options, Precision-Based Medicine a Focus for Ovarian Cancers


In this clip, Maurie Markman, MD, discusses ovarian cancer as a chronic illness, and an increasing need for precision medicine.

The range of options for treating gynecologic malignancies is expanding with approved targeted agents and a greater focus on maintaining quality of life (QoL). According to Maurie Markman, MD, who has been in the field for decades, the field is moving in a precision-based medicine direction, with an expanding array of options for managing patients.

Within the last few years, 3 FDA-approved PARP inhibitors have altered the way oncologists treat select patients with ovarian cancer. In May 2018, rucaparib (Rubraca) joined niraparib (Zejula) and olaparib (Lynparza) as having maintenance-setting indications for the treatment of patients who are in complete or partial response to platinum-based chemotherapy. Combination therapies that incorporate immunotherapy are also being studied.

In this clip, Markman discusses ovarian cancer as a chronic illness, and the increasing focus on precision medicine.

Related Videos
Diabetes patient turn knob on end of insulin pen and dial up correct insulin dose for injection. Scale window on pen syringe showing number of units dose. Medical equipment is easy to self injection - Image credit: Orawan | stock.adobe.com
Laboratory test tubes and solution with stethoscope background | Image Credit: Shutter2U - stock.adobe.com
Image credit: Andrea Izzotti
Inflation Reduction Act is shown using the text and the US flag - Image credit: Andrii | stock.adobe.com
3D illustration of heart
Model of a heart
Man experiencing heart pain
3D illustration of heart
© 2023 MJH Life Sciences

All rights reserved.